Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHIRON VISION VITRASERT IMPLANT FOR CMV RETINITIS AVAILABLE FOLLOWING APPROVAL MARCH 4; ROCHE WILL MARKET TO PRIMARY CARE AND INFECTIOUS DISEASE MARKETS

Executive Summary

Chiron Vision is beginning immediate shipments of Vitrasert following the March 4 approval of the ganciclovir intraocular implant for cytomegalovirus retinitis treatment in people with AIDS.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS027775

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel